Hormone Therapy

2 for Obesity

Oregon Health & Science University, Portland, OR
Targeting 2 different conditionsEstrogen cream +4 moreN/AWaitlist AvailableLed by Jonathan Q. Purnell, M.D.Research Sponsored by Oregon Health and Science University

Study Summary

This trialinvestigates if hormones affect how fat is stored in the body and how stress hormones are affected.

Eligible Conditions
  • Obesity
  • Menopause


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before and after hormone replacement therapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and before and after hormone replacement therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To measure 24-hour CPR, free cortisol, and cortisol binding globulin levels in plasma; HSD 1 activity, glucocorticoid receptor binding, and cortisol levels in adipocytes; and urinary excretion of cortisol, cortisone and their metabolites.
Secondary outcome measures
To measure intramyocellular fat and intrahepatic fat by MRS, visceral and subcutaneous abdominal fat by CT scan, body composition (fat mass, lean mass, and bone mass) by DXA, and insulin sensitivity.

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

5Treatment groups
Active Control
Placebo Group
Group I: 2Active Control1 Intervention
Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
Group II: 3Active Control1 Intervention
Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
Group III: 5Active Control1 Intervention
Women on estrogen cream
Group IV: 1Placebo Group1 Intervention
Men on placebo injections for 4 months
Group V: 4Placebo Group1 Intervention
Women on placebo cream

Find a site

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
931 Previous Clinical Trials
6,829,959 Total Patients Enrolled
29 Trials studying Obesity
9,199 Patients Enrolled for Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,245 Previous Clinical Trials
4,198,767 Total Patients Enrolled
421 Trials studying Obesity
495,520 Patients Enrolled for Obesity
Jonathan Q. Purnell, M.D.Principal Investigator
OHSU - Center for the Study of Weight Regulation
4 Previous Clinical Trials
123 Total Patients Enrolled
4 Trials studying Obesity
123 Patients Enrolled for Obesity

Media Library

Depo Lupron/Aromatase inhibitor (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00694733 — N/A
Obesity Research Study Groups: 1, 2, 3, 4, 5
Obesity Clinical Trial 2023: Depo Lupron/Aromatase inhibitor Highlights & Side Effects. Trial Name: NCT00694733 — N/A
Depo Lupron/Aromatase inhibitor (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00694733 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What maladies is 2 typically administered to treat?

"2 is a common treatment for hormone receptor unknown, and its efficacy has been established in cases of orchidectomy, orchitis, as well as advanced prostate cancer."

Answered by AI

Is it permissible for minors to participate in this investigation?

"As specified in the eligibility criteria, only patients between 18 to 62 years old can take part in this trial. For younger and older individuals respectively, there are 214 trials and 764 trials available for them to enroll into."

Answered by AI

Who meets the eligibility criteria for this experiment?

"In order to enrol in the trial, individuals should possess obesity and be within the ages of 18-62. The research team is expecting to attract 140 participants overall."

Answered by AI

What is the maximum size of enrollees in this research study?

"This clinical trial has already reached their specified enrollment and is no longer recruiting patients. This study initially appeared on May 1st 2005, with the last edit to its page occurring on August 5th 2019. If you are searching for other medical trials involving obesity, there are 973 studies actively seeking participants while 206 more open investigations require two or more patients."

Answered by AI

Are there any other empirical investigations involving 2?

"Currently, 206 active clinical trials are investigating the efficacy of 2 with 58 such studies in Phase 3. Duarte, California is one location where a lot of research on this drug is conducted. However, there are 12370 sites around the world working to further our understanding of its potential use cases."

Answered by AI

Are recruitment opportunities still available for this clinical trial?

"According to the clinicaltrials.gov, this trial is not looking for candidates as of now; it was initially posted on May 1st 2005 and last modified on August 5th 2019. Nevertheless, 1179 other medical trials are currently seeking enrollees."

Answered by AI
~3 spots leftby Mar 2024